Table 2. Stratified analysis of XPG Asp1104His and XPF Arg415Gln polymorphisms on cancer risk. 1 .
| Genetic model | N | Recessive model | Dominant model | Homozygote | Heterozygote | Additive model | |||||
| OR (95%CI) | Ph/I2 (%) | OR (95%CI) | Ph/I2 (%) | OR (95%CI) | Ph/I2 (%) | OR (95%CI) | Ph/I2 (%) | OR (95%CI) | Ph/I2 (%) | ||
| XPG Asp1104His | |||||||||||
| Overall | 66 (32162/39858) | 1.00 (0.94–1.07)* | 0.073/21.2 | 1.05 (1.00–1.10)* | 0.001/40.4 | 1.04 (0.96–1.12)* | 0.012/30.9 | 1.06 (1.01–1.11)* | <0.001/43.3 | 1.03 (0.99–1.06)* | 0.008/32.8 |
| Cancer type | |||||||||||
| Bladder cancer | 7 (2488/2809) | 1.06 (0.72–1.56)* | 0.041/56.8 | 1.10 (0.85–1.44)* | 0.001/74.9 | 1.11 (0.69–1.80)* | 0.006/69.7 | 2 | <0.001/77.5 | 2 | <0.001/77.7 |
| Breast cancer | 11 (5474/6157) | 0.95 (0.83–1.09) | 0.173/28.6 | 1.01 (0.94–1.09) | 0.128/33.8 | 0.99 (0.86–1.14) | 0.185/27.2 | 1.02 (0.94–1.10) | 0.136/32.8 | 1.00 (0.93–1.09)* | 0.098/37.8 |
| Colorectal cancer | 7 (3471/3638) | 0.91 (0.77–1.08) | 0.696/0.0 | 1.07 (0.88–1.29)* | 0.004/69.1 | 1.08 (0.89–1.30) | 0.411/0.7 | 1.11 (0.86–1.42)* | <0.001/78.0 | 1.03 (0.95–1.12) | 0.169/35.7 |
| Glioma | 3 (1719/2789) | 0.98 (0.81–1.19) | 0.262/25.3 | 1.03 (0.90–1.18) | 0.984/0.0 | 0.97 (0.78–1.19) | 0.322/0.0 | 1.06 (0.92–1.23) | 0.810/0.0 | 1.01 (0.91–1.12) | 0.774/0.0 |
| HNC | 5 (1709/2691) | 0.92 (0.74–1.15) | 0.114/46.4 | 1.01 (0.89–1.16) | 0.244/26.6 | 0.86 (0.67–1.10) | 0.257/24.6 | 1.05 (0.83–1.31)* | 0.087/50.8 | 0.99 (0.90–1.10) | 0.735/0.0 |
| NHL | 4 (2303/2176) | 1.06 (0.84–1.35) | 0.389/0.6 | 1.12 (0.99–1.26) | 0.117/49.2 | 1.11 (0.88–1.42) | 0.279/22.0 | 1.12 (0.99–1.27) | 0.194/36.3 | 1.11 (0.95–1.29)* | 0.087/54.4 |
| Lung cancer | 7 (5509/6867) | 1.04 (0.93–1.17) | 0.212/28.4 | 1.13 (0.98–1.31)* | 0.045/53.4 | 1.15 (0.94–1.42)* | 0.071/48.3 | 1.13 (0.98–1.31)* | 0.077/47.3 | 1.08 (0.98–1.19)* | 0.073/48.0 |
| Melanoma | 8 (5297/7072) | 0.87 (0.69–1.12)* | 0.050/50.3 | 0.97 (0.90–1.04) | 0.762/0.0 | 0.87 (0.68–1.11)* | 0.059/48.4 | 0.98 (0.90–1.06) | 0.854/0.0 | 0.97 (0.91–1.03) | 0.336/12.1 |
| Other cancer | 14 (4192/5659) | 1.07 (0.93–1.22) | 0.578/0.0 | 1.06 (0.97–1.15) | 0.406/4.1 | 1.12 (0.96–1.30) | 0.533/0.0 | 1.05 (0.96–1.15) | 0.290/14.9 | 1.05 (0.98–1.12) | 0.675/0.0 |
| XPF Arg415Gln | |||||||||||
| Overall | 32 (17864/20578) | 1.11 (0.81–1.52)* | 0.068/30.5 | 1.04 (0.93–1.15)* | <0.001/62.6 | 1.10 (0.79–1.54)* | 0.035/35.7 | 1.02 (0.91–1.14)* | <0.001/62.5 | 1.05 (0.94–1.16)* | <0.001/66.7 |
| Cancer type | |||||||||||
| Breast cancer | 10 (5086/5542) | 1.22 (0.82–1.83)* | 0.017/58.9 | 1.03 (0.92–1.15) | 0.167/30.2 | 1.18 (0.76–1.83)* | 0.007/63.8 | 0.99 (0.87–1.12) | 0.277/18.6 | 1.01 (0.83–1.22)* | 0.034/52.0 |
| Lung cancer | 3 (2857/3118) | 0.75 (0.40–1.41) | 0.491/0.0 | 0.82 (0.71–0.96) | 0.104/55.7 | 0.73 (0.39–1.37) | 0.466/0.0 | 0.83 (0.71–0.97) | 0.132/50.7 | 0.83 (0.72–0.95)* | 0.091/58.4 |
| HNC | 4 (1643/2156) | 1.47 (0.72–2.98) | 0.364/5.8 | 1.04 (0.88–1.23) | 0.359/6.9 | 1.48 (0.73–3.00) | 0.370/4.5 | 1.02 (0.86–1.21) | 0.323/13.9 | 1.05 (0.90–1.23) | 0.302/17.7 |
| Colorectal cancer | 4 (1501/1497) | 0.51 (0.06–4.35)* | 0.069/69.7 | 0.93 (0.76–1.14) | 0.605/0.0 | 0.51 (0.06–4.45)* | 0.067/70.3 | 0.93 (0.74–1.18) | 0.526/0.0 | 0.90 (0.72–1.11) | 0.315/13.4 |
| Glioma | 3 (874/1359) | 1.51 (0.83–2.74) | 0.368/0.0 | 2 | <0.001/87.0 | 1.61 (0.88–2.93) | 0.357/3.0 | 2 | <0.001/88.0 | 2 | 0.001/86.0 |
| Other cancer | 8 (5903/6906) | 1.03 (0.69–1.53) | 0.239/24.9 | 0.95 (0.82–1.10)* | 0.048/50.6 | 1.02 (0.68–1.52) | 0.254/23.0 | 0.95 (0.82–1.11)* | 0.040/52.3 | 0.96 (0.84–1.09)* | 0.067/47.0 |
1
All summary ORs were calculated using fixed-effects models. In the case of significant heterogeneity (indicated by *), ORs were calculated using random-effects models.
2
The results were excluded due to high heterogeneity. The bold values indicate that the results are statistically significant.